Hospital-acquired pneumonia medical therapy
|
Hospital-acquired pneumonia Microchapters |
|
Differentiating Hospital-Acquired Pneumonia from other Diseases |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hospital-acquired pneumonia medical therapy On the Web |
|
American Roentgen Ray Society Images of Hospital-acquired pneumonia medical therapy |
|
Directions to Hospitals Treating Hospital-acquired pneumonia |
|
Risk calculators and risk factors for Hospital-acquired pneumonia medical therapy |
Editor(s)-in-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Philip Marcus, M.D., M.P.H.[2]
Overview
Antimicrobial therapy
Patients prone to Methicillin-resistant staphylococcus aureus
- Critically ill patients
- History of recent antibiotic therapy
- Patient admitted in a hospital with increased incidence of MRSA.
Antibiotic choice for MRSA
- Vancomycin
- Linezolid
- Teicoplanin
- In case no MRSA is isolated on culture these antibiotics should be discontinued.
Supportive trial data [1]
Side-effects of Linezolid
- Thrombocytopenia
- Gastrointestinal side-effects
- Renal dysfunction
Side-effects of vancomycin
- Renal toxicity were more common in vancomycin compared to linezolid
References
- ↑ Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J (2012). "Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study". Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. 54 (5): 621–9. doi:10.1093/cid/cir895. PMID 22247123. Retrieved 2012-09-11. Unknown parameter
|month=ignored (help)